Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Znomics launches obesity drug discovery program
Znomics obtained from Oregon Health & Science University (OHSU), an exclusive biological license to a genetic model of obesity using the zebrafish developed in the OHSU laboratory of
Znomics obtained from Oregon Health & Science University (OHSU), an exclusive biological license to a genetic model of obesity using the zebrafish developed in the OHSU laboratory of
This decision was based upon positive clinical data generated in a 500-subject, Phase I/II study recently completed by Iomai. Guided by data from this study, Iomai will begin
PH-10 is currently undergoing Phase II clinical testing in New York City for the treatment of moderate to severe psoriasis, and Provectus expects to commence Phase II testing
The European Agency for the Evaluation of Medicinal Products (EMEA) established small and medium-sized enterprise (SME) as a dedicated office in 2005 to provide special assistance to small
In the preclinical studies, the combination therapy had an additive effect, inhibiting tumor growth by up to 97% in an irinotecan-resistant mouse xenograft model of colorectal cancer (HT29),
The product will be launched in Germany and Denmark in the coming weeks, followed soon by Ireland, the UK and the rest of EU, and when approved also
This test will enable couples who are planning a pregnancy, or who are already pregnant, to determine if they are carriers and at risk of having a baby
The company expects to present top-line results of this confirmatory Phase III trial by the end of the first half of 2008. The trial is a 400-patient, multi-center,
Under the agreement, eResearchTechnology (eRT) and nSpire will deliver a combined solution to meet the increased demand for cardio-pulmonary safety and efficacy services during clinical trials, in part
Basilea is currently conducting pivotal randomized Phase III studies focusing on first-line treatment against invasive aspergillus or candida bloodstream infections. This additional supportive international multicenter safety and efficacy